
Rivia is a unified data and AI analytics platform designed for biotech and pharmaceutical companies to optimize clinical trials. It integrates fragmented trial data from multiple vendor sources into…

Rivia is a unified data and AI analytics platform designed for biotech and pharmaceutical companies to optimize clinical trials. It integrates fragmented trial data from multiple vendor sources into…
What they do: Unified clinical-trial data & AI analytics platform (Rivia Core, Rivia Detect, Rivia Spark) for biotech and pharma
Headquarters: Zürich, Switzerland
Founding year: 2022
Stage / recent raise: Series A reported March 2026 (~€13M / ~$14.7M)
Notable investors: Earlybird, Speedinvest, Amino Collective, Nina Capital, Defiant
Clinical trial data fragmentation, data quality and slow decision-making in drug development.
2022
Software Development
€3,000,000
Reported seed round (~€3M) with participation from Speedinvest, Amino Collective and Nina Capital.
€13,000,000
Series A reported March 2026; reported amounts vary (~€13M / €14.7M reported in some coverage).
“Participation from European VCs (Earlybird, Speedinvest, Amino Collective, Nina Capital, Defiant) indicates institutional VC backing and cross-border investor interest”
About Rivia
Rivia is a technology company building a data engine that powers the future of clinical trial intelligence. Rivia was founded on the belief that new drugs can be brought to market more successfully with a fraction of today's capital.
Biotechs are the source of most therapeutic innovation, yet clinical development is constantly constrained by fragmented data and outdated tooling. Rivia unifies clinical trial data at scale through a core engine built as a reusable intelligence layer, comprising hundreds of configurations and trial-specific logic, independent of source structure. This vertical stack of data engine, workflows, and agents creates a distinct advantage in how trials are operated.
Over the past two years, European and US based biotechs running global clinical trials on Rivia have demonstrated measurable impact, from earlier understanding of therapeutic potential to significantly more efficient trial execution. In March 2026, Rivia raised its $15M Series A led by Earlybird Venture Capital.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week
| Company |
|---|
Rivia’s ambition is to become the standard infrastructure for modern drug development, transforming how trials are executed end-to-end.
The Role
As QA Manager at Rivia, you will take full ownership of the company's compliance and quality function. You will be the single point of accountability for GCP compliance and required certification including ISO 27001 (ISMS), ISO 9001 (QMS), and GAMP 5 software validation. You will inherit a functioning compliance programme from the founders and build it into a robust, scalable asset as the company grows.
Rivia is already compliant, this role is about taking ownership, deepening maturity, and ensuring that compliance is both a source of trust and a competitive advantage as the company scales toward 35+ people and expands its client base.
What Excites You
Responsibilities
What Excites Us
Our Values
At Rivia, we are committed to excellence, continuous learning, and the success of both our customers and our team. If you are driven to exceed targets, eager to shape the future of clinical trials, and passionate about making a meaningful difference in the biotech industry, Rivia is the place for you.